China Pharma Holdings, Inc. Rescinds Securities Purchase Agreement
CPHI Stock | USD 0.23 0.01 4.17% |
Under 62% of China Pharma's investor base is looking to short. The analysis of overall sentiment of trading China Pharma Holdings stock suggests that many investors are alarmed at this time. China Pharma's investing sentiment shows overall attitude of investors towards China Pharma Holdings.
China |
China Pharma Holdings, Inc. recently announced a significant development regarding the termination of a material definitive agreement. On December 23, 2024, the company successfully reached an agreement with a specific investor to rescind a securities purchase agreement that was initially dated December 12, 2024. This mutual decision was noted as the Recission and
Read at thelincolnianonline.com
China Pharma Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards China Pharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
China Pharma Fundamental Analysis
We analyze China Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of China Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of China Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash And Equivalents
Cash And Equivalents Comparative Analysis
China Pharma is currently under evaluation in cash and equivalents category among its peers. Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
China Pharma Holdings Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with China Pharma stock to make a market-neutral strategy. Peer analysis of China Pharma could also be used in its relative valuation, which is a method of valuing China Pharma by comparing valuation metrics with similar companies.
Peers
China Pharma Related Equities
LFCR | Lifecore Biomedical | 14.41 | ||||
SHPH | Shuttle Pharmaceuticals | 9.41 | ||||
SXTC | China SXT | 6.12 | ||||
UPC | Universe Pharmaceuticals | 4.92 | ||||
BFRI | Biofrontera | 2.75 | ||||
AKAN | Akanda Corp | 1.18 | ||||
SNOA | Sonoma Pharmaceuticals | 1.49 | ||||
PTPI | Petros Pharmaceuticals | 14.89 |
Complementary Tools for China Stock analysis
When running China Pharma's price analysis, check to measure China Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy China Pharma is operating at the current time. Most of China Pharma's value examination focuses on studying past and present price action to predict the probability of China Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move China Pharma's price. Additionally, you may evaluate how the addition of China Pharma to your portfolios can decrease your overall portfolio volatility.
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |